GLP-1受体激动剂是否增加乳腺癌风险?系统综述与荟萃分析
该系统综述与荟萃分析纳入52项随机对照试验,评估GLP-1受体激动剂(GLP-1RA)治疗肥胖和/或糖尿病是否增加乳腺肿瘤风险。结果显示,GLP-1RA组与对照组乳腺癌风险无显著差异(RR 0.98,95%CI 0.76-1.26),良性乳腺肿瘤风险亦无差异(RR 0.99,95%CI 0.48-2.01)。结论认为GLP-1RA不增加乳腺癌风险。
要点
- GLP-1RA治疗不增加乳腺癌风险(RR 0.98,95%CI 0.76-1.26)。
- 良性乳腺肿瘤风险亦无显著差异(RR 0.99,95%CI 0.48-2.01)。
- 亚组分析(随访时间、盲法、药物类型)未见差异。
核心结论
- GLP-1RA用于肥胖和糖尿病治疗不增加乳腺肿瘤风险。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase、Web of Science和CENTRAL(2019年7月31日至2020年2月8日)。
- 纳入52项随机对照试验,受试者为超重/肥胖和/或糖尿病成人,随访至少24周。
- 50项试验报告乳腺癌事件,11项报告良性乳腺肿瘤;采用RoB 2.0评估偏倚风险,GRADE评估证据质量。
主要发现
- 良性乳腺肿瘤风险组间无差异(RR 0.99,95%CI 0.48-2.01)。
- 按随访时间、参与者/研究者盲法及GLP-1RA类型进行的亚组分析未显示差异。
- 试验序贯分析提示样本量足以避免遗漏替代结果。
临床怎么用
- 对于肥胖或糖尿病患者,使用GLP-1RA时无需因乳腺癌风险担忧而限制其应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Risk of cancer is a major concern in the development of drugs for the treatment of obesity and diabetes. In randomized controlled trials (RCTs) of the Liraglutide Clinical Development Program, subjects treated with a glucagon-like peptide-1 receptor agonist (GLP-1RA) had a higher absolute number of breast cancer events. OBJECTIVE: To assess whether patients treated with GLP-1RAs had a higher risk of breast neoplasms. DATA SOURCES: We searched MEDLINE, Embase, Web of Science, and CENTRAL from July 31, 2019 to February 8, 2020. STUDY SELECTION: Reviewers assessed abstracts and full-text articles for RCTs of GLP-1RAs in adults with excessive weight and/or diabetes and a minimum follow-up of 24 weeks. DATA EXTRACTION: Researchers extracted study-level data and assessed within-study risk of bias with the RoB 2.0 tool and quality of evidence with Grading of Recommendations Assessment, Development and Evaluation (GRADE). DATA SYNTHESIS: We included 52 trials, of which 50 reported breast cancer events and 11 reported benign breast neoplasms. Overall methodological quality was high. Among 48 267 subjects treated with GLP-1RAs, 130 developed breast cancer compared with 107 of 40 755 controls (relative risk [RR], 0.98; 95% confidence interval [CI], 0.76-1.26). Subset analyses according to follow-up, participant/investigator blinding, and type of GLP-1RA did not reveal any differences. The risk of benign breast neoplasms also did not differ between groups (RR, 0.99; 95% CI, 0.48-2.01). Trial sequential analysis provided evidence that the sample size was sufficient to avoid missing alternative results. CONCLUSIONS: Treatment with GLP-1RAs for obesity and diabetes does not increase the risk of breast neoplasms.
引用
- Piccoli GF, Mesquita LA, Stein C, et al. Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2021. PMID: 33248445. doi:10.1210/clinem/dgaa891
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。